THE DEAL, AT A GLANCE
From the announcementVeracyte
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedVeracyte raised $100M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersVeracyte is using Growth Round financing to extend AI genomic diagnostics beyond thyroid cancer classification into breast and lung cancer.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Veracyte · Financing Record
Explore source-linked visual explanations for Veracyte. Unsupported claims are withheld while source review continues.
Record 494 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →